Clinical Report: FDA OKs Linaclotide in Young Children

Overview

The FDA has approved linaclotide for pediatric patients aged 2 years and older with functional constipation, expanding its indication to include children aged 2 to 5 years. This approval is significant as linaclotide is the only FDA-approved prescription therapy specifically for pediatric functional constipation.

Background

Functional constipation is a common condition in preschool-aged children, characterized by infrequent and painful bowel movements. The estimated prevalence among this age group is approximately 3%. The approval of linaclotide provides a new evidence-based treatment option for managing this challenging condition in young children, who often do not respond to over-the-counter therapies, which may be insufficient or ineffective.

Data Highlights

Key Findings

• Linaclotide is now approved for children aged 2 years and older with functional constipation.
• The approval was based on a 12-week phase 3 randomized placebo-controlled trial.
• Linaclotide improved bowel movement frequency compared to placebo.
• The safety profile is consistent with previous studies in older pediatric patients and adults.
• Diarrhea was the most commonly reported adverse reaction in clinical trials, necessitating careful monitoring.

Clinical Implications

Clinicians can now prescribe linaclotide for young children with functional constipation, offering a new treatment avenue when traditional therapies fail. It is important to educate parents on the proper administration of the medication, which can be mixed with applesauce or water for easier intake, and to monitor for potential adverse effects, particularly diarrhea.

Conclusion

The FDA's approval of linaclotide for young children marks a significant advancement in the management of functional constipation, providing healthcare professionals with a new tool to address this prevalent condition, especially in cases where existing treatments are inadequate.

Related Resources & Content

1. Ironwood Pharmaceuticals, Inc., FDA Approves Use of LINZESS® in Pediatric Patients, 2026 -- FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
2. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients, ScienceDirect, 2023 -- Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
3. The New Gastroenterologist — FDA Grants Approval for Simponi in Treating Pediatric Ulcerative Colitis
4. The New Gastroenterologist — Mirikizumab demonstrates potential benefits for children suffering from ulcerative colitis
5. the asco post — FDA Approves Kinase Inhibitor for Pediatric Patients With NF1
6. the asco post — FDA Approves Taletrectinib for ROS1-Positive Non–Small Cell Lung Cancer
7. Ironwood Pharmaceuticals, Inc. - FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
8. Efficacy and safety of pharmacological therapies for functional constipation in children: a systematic review and meta-analysis - ScienceDirect
9. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial - ScienceDirect
10. Safety and efficacy of linaclotide in children aged 2-5 years with functional constipation: Phase 2, randomized study - PubMed
11. DailyMed - LINZESS- linaclotide capsule, gelatin coated